{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:13:54Z","timestamp":1761498834394,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.beha.2022.101408","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T22:26:57Z","timestamp":1667082417000},"page":"101408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consolidation chemotherapy in AML: Are we playing with a full deck of cards?"],"prefix":"10.1016","volume":"35","author":[{"given":"Richard M.","family":"Stone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2022.101408_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101408_bib2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","article-title":"Cytarabine and daunorubicin for the treatment of acute myeloid leukemia","author":"Murphy","year":"2017","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.beha.2022.101408_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 Trial","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101408_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC_GIMEMA AML -12 trial","author":"Willemze","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101408_bib5","first-page":"822","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"811","author":"Kico","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.beha.2022.101408_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101408_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101408_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101408_bib9","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","article-title":"FDA Approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia","author":"Jen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2022.101408_bib10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.leukres.2013.05.013","article-title":"Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes","author":"Sherman","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2022.101408_bib11","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2022.101408_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-021-00503-6","article-title":"Core binding factor acute myelogenous leukemia-2021 treatment algorithm","volume":"11","author":"Borthakur","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2022.101408_bib13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomized controlled trials","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2022.101408_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101408_bib15","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2022.101408_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11899-013-0156-3","article-title":"High-dose cytarabine (HD araC) in the treatment of leukemias: a review","author":"Reese","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.beha.2022.101408_bib17","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novl acute myeloid leukaemia (ALFA-0701): a randomized, open-label, phase 3 study","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2022.101408_bib18","doi-asserted-by":"crossref","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. doi.org\/10.1182\/blood.2022016867.","DOI":"10.1182\/blood.2022016867"},{"key":"10.1016\/j.beha.2022.101408_bib19","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2017-04-777722","article-title":"Cytarabine dose in the consolidation treatment of AML: a systemic review and meta-analysis","volume":"130","author":"Magina","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101408_bib20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41409-020-01129-1","article-title":"ELN risk stratification and outcomes in secondary and therapy-relate AML patients consolidated with allogeneic stem cell transplantation","volume":"56","author":"Jentzsch","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2022.101408_bib21","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3324\/haematol.2017.181180","article-title":"Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome-not because we can, but because we should","volume":"102","author":"Cutler","year":"2017","journal-title":"Haematol"},{"key":"10.1016\/j.beha.2022.101408_bib22","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: a systemic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.beha.2022.101408_bib23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","article-title":"Allogeneic transplantation versus chemotherapy as postremissoin therapy for acute myeloid leukemia: a prospective matched pairs analysis","volume":"32","author":"Stelljes","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101408_bib24","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.20.01170","article-title":"Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses","volume":"39","author":"Burnett","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101408_bib25","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101408_bib26","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systemic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beha.2022.101408_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jtct.2020.12.014","article-title":"Pretransplantation MRD in older patients with AML after treatment with decitabine or conventional chemotherapy","volume":"27","author":"Hilberink","year":"2021","journal-title":"Transplantation and cellular therapy"},{"key":"10.1016\/j.beha.2022.101408_bib28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2022.101408_bib29","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101408_bib30","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutation","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"year":"2021","series-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \u201cwhen and for whom\u201d in 2021?","author":"Gagelmann","key":"10.1016\/j.beha.2022.101408_bib31"},{"key":"10.1016\/j.beha.2022.101408_bib32","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"35","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101408_bib33","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacytidine maintenance therapy for acute myeloid leukemia in first remission","volume":"26","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101408_bib34","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacytidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2022.101408_bib35","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacytidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101408_bib36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminhematol.2007.08.002","article-title":"Acute myeloid leukemia and the position of autologous stem cell transplantation","volume":"44","author":"Breems","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2022.101408_bib37","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101408_bib38","article-title":"AML-029 Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnose FLT3-ITD+AML","author":"Erba","year":"2022","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.beha.2022.101408_bib39","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia; the Alliance CALGB 10603\/RATIFY trial","volume":"35","author":"Larson","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2022.101408_bib40","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101408_bib41","first-page":"699","article-title":"Safety and efficacy of menin inhibition in patients with MLL-rearranged and NPM1 mutant acute leukemia: a phase I, first-in-human study of SNDX-5613 (AUGMENT 101)","volume":"vol. 138","author":"Stein","year":"2021"},{"key":"10.1016\/j.beha.2022.101408_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"53","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2022.101408_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","article-title":"Bispecific antibodies for the treatment of acute myeloid leukemia","volume":"13","author":"Guy","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.beha.2022.101408_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101408_bib45","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1158\/1078-0432.CCR-20-2149","article-title":"Development of highly optimized antibody-drug conjugates against CD33 and CD123 for acute myeloid leukemia","volume":"27","author":"Han","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2022.101408_bib46","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1182\/blood-2021-147486","article-title":"Safety and efficacy of combining tagraxofusp (SL-401) with azacytidine or azacytidine and venetoclax in a phase 1b study for CD123 positive AML, MDS, or BPDCN","volume":"138","author":"Lane","year":"2021","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:25Z","timestamp":1761498445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692622000639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521692622000639"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2022.101408","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidation chemotherapy in AML: Are we playing with a full deck of cards?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2022.101408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101408"}}